fda compounding semaglutide warning letter news Compounded "semaglutide" is not FDA-approved Drugs | FDA

Semaglutide-induced nausea typically peaks during dose escalation and often resolves within 24 weeks as your body adapts to the medication

Key research findings include: Average 24.2% body weight reduction in Phase 2 at the highest dose cohort over 48 weeks Significant reductions in waist circumference, triglycerides, and fasting glucose Weekly subcutaneous injection (half-life approximately 6 days) Most common adverse events: nausea, vomiting, diarrhea (typical of GLP-1 class) Requires cold chain storage (28C refrigerated)

Hongda Phytochemistry's manufacturing facilities hold ISO 9001:2015 quality management certification alongside pharmaceutical-specific cGMP, ISO22000, and FSSC22000 certifications

[Dedov II, Shestakova MV, Mayorov AY, et al

The Phase 3 ACHIEVE-2 trial compared oral orforglipron with dapagliflozin in 962 adults with type 2 diabetes taking metformin

Data Availability: All relevant data are within the paper and its Supporting Information files